Navigation Links
Pharmos Corporation Reports 2007 Third Quarter Results
Date:10/30/2007

on due to the aforementioned lower professional fees and investor relations costs in connection with the Company's acquisition of Vela Pharmaceuticals in 2006, as well as to a reduction in insurance costs during the first half 2007. These reductions are offset in part by a $0.3 million consulting fee paid in 2007 to a former officer in accordance with the officer's employment agreement. Net other income decreased to $0.8 million in the current year-to-date period from $1.4 million in the same period in 2006, due primarily to a decrease in interest income.

Net Operating Loss Shareholder Notice

Under Internal Revenue Code Section 382 rules, a change in ownership can occur whenever there is a shift in ownership by more than 50 percentage points by one or more five-percent shareholders within a three-year period. When a change of ownership is triggered, the Company's net operating losses (NOL) asset may be impaired. The Company believes that substantially all of its Federal NOL generated since 1995 are not impaired, and requests that all investors contact the Company prior to allowing their ownership interest to reach a five-percent level.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with irritable bowel syndrome (IBS). Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second clinical program currently in Phase 2a testing is Pharmos' proprietary NanoEmulsion cream drug delivery system formulated with the NSAID diclofenac, which is being studied
'/>"/>

SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. Sonic Foundry reports GAAP loss as Q2 revenues rise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Staying true to their mission of ... product that makes the world a better place, the ... Institute (GBSI) to redesign their website ( http://www.gbsi.org ) ... strategy-based. , "Biomedical research is not always an easy ... promote it in a narrative way on a website," ...
(Date:4/21/2015)... 2015 Invetech , a global ... and contract manufacturing, and  NanoCellect Biomedical, a ... cell sorting technology for life science researchers, today ... cytometry platform. Headquartered in ... a microchip-based cell sorting technology. NanoCellect,s flow cytometry ...
(Date:4/21/2015)...  Tute Genomics, a leading provider of cloud-based genomic medicine ... as VP of Marketing. Mr. Forsythe is the latest to ... its commercial operations over the last two quarters. ... is a tremendous addition to the Tute Genomics team," ... Genomics. "Josh,s vast experience commercializing software technology in a highly ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that it ... market open on Tuesday, April 28, 2015. ... April 28, 2015, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... Aug. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. ("MIGENIX"),announced today ... Holdings,Inc. ("DJohnson"), a significant shareholder of MIGENIX, that ... of shareholders scheduled for,October 31, 2008. As part ... of,its board of directors from seven members to ...
... CLAREMONT, Calif., Aug. 11 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... the second quarter of 2008 ended June 30 ... $1,872,647 for the second,quarter of 2007. Revenues for ... 60% from the previous year., The significant ...
... 4:30 p.m. Eastern Time -, SAN FRANCISCO, Aug. ... on its corporate progress and financial,results for the quarter ... findings of the Dimebon 12-month pivotal,trial in Alzheimer,s disease ... results from our Phase 2 study in Huntington,s disease,announced ...
Cached Biology Technology:Migenix averts proxy contest; reaches agreement with DJohnson holdings 2Migenix averts proxy contest; reaches agreement with DJohnson holdings 3Migenix averts proxy contest; reaches agreement with DJohnson holdings 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 2Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 5Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 6Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 7Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 8Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 9Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 8
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... 2007 (Aliso Viejo, California) Ossur, an emerging leader ... a period of integration, is pleased to announce that ... of a two year cervical collar study performed by ... Tissue Interface Pressure from Four Cervical Collars, finds ...
... National Science Foundation has awarded Joan Edwards, the Washington ... professor of physics at Pomona College, a grant in ... of a high-speed imaging facility at Williams College for ... applications in the sciences. The project builds on ...
... researchers, in collaboration with the International Maize and ... research illustrates the major genetic improvements possible without ... use wild relatives of wheat as sources of ... team leader Dr Phil Larkin says. Unfortunately ...
Cached Biology News:Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2NSF awards Williams funding for high-speed imaging faciltity 2Building disease-beating wheat 2
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Human FADD Affinity Purified Polyclonal Ab...
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Biology Products: